Nan Fung Trinity HK Ltd. Purchases Shares of 80,775 Celcuity, Inc. $CELC

Nan Fung Trinity HK Ltd. purchased a new stake in Celcuity, Inc. (NASDAQ:CELC) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 80,775 shares of the company’s stock, valued at approximately $8,056,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Sequoia Financial Advisors LLC purchased a new stake in Celcuity in the fourth quarter valued at $425,000. Truist Financial Corp purchased a new stake in Celcuity in the fourth quarter valued at $299,000. WoodTrust Financial Corp lifted its position in Celcuity by 10.8% in the fourth quarter. WoodTrust Financial Corp now owns 6,207 shares of the company’s stock valued at $619,000 after acquiring an additional 607 shares during the last quarter. Jennison Associates LLC purchased a new stake in Celcuity in the fourth quarter valued at $22,911,000. Finally, State of New Jersey Common Pension Fund D purchased a new stake in Celcuity in the fourth quarter valued at $433,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. The trade was a 57.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the transaction, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This represents a 27.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 37,000 shares of company stock worth $5,111,950. 13.33% of the stock is currently owned by company insiders.

Celcuity Trading Up 0.3%

NASDAQ CELC opened at $131.06 on Friday. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55. The firm has a market cap of $6.34 billion, a PE ratio of -34.58 and a beta of 0.09. Celcuity, Inc. has a one year low of $9.51 and a one year high of $151.02. The firm’s fifty day moving average is $116.46 and its two-hundred day moving average is $104.45.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. Analysts expect that Celcuity, Inc. will post -3.87 earnings per share for the current year.

Wall Street Analyst Weigh In

CELC has been the subject of a number of research reports. Craig Hallum reissued a “buy” rating and issued a $189.00 price target on shares of Celcuity in a research report on Monday, May 4th. Citizens Jmp boosted their price target on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a research report on Monday, May 4th. Stifel Nicolaus set a $150.00 price target on shares of Celcuity in a research report on Monday, May 4th. Wolfe Research reissued an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a research report on Thursday, March 12th. Finally, Citigroup reissued an “outperform” rating on shares of Celcuity in a research report on Monday, May 4th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Celcuity presently has an average rating of “Moderate Buy” and an average price target of $134.50.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.